R&D Pipeline

Teduglutide Preclinical studies of teduglutide for pediatric indications have been conducted.

NPSP795 Small molecule antagonists of the calcium receptor, which may have clinical application in treating rare endocrine disorders such as ADH.

NPSP790 Small molecule antagonists of the calcium receptor, which may have clinical application in treating rare endocrine disorders such as ADH.

Teduglutide in other indications A Phase 2 study of teduglutide has been completed in moderate-to-severe Crohn's disease.

Natpara^® A bioengineered replica of human parathyroid hormone, being studied as a hormone replacement for the treatment of hypoparathyroidism.

Gattex^® 0.05 mg/kg/d (Teduglutide [rDNA origin]) for Injection is FDA-approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support.

"SBS and hypoparathyroidism are rare disorders with significant unmet needs and serious complications. We believe the successful development of Gattex and Natpara for these indications could provide patients with important clinical benefits, which could improve patients' lives."

Roger Garceau, MD
Senior Vice President and Chief Medical Officer

	Contact Us